Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics, announces the results of the Annual General Meeting (AGM) held today on June 15, 2022. The shareholders approved all resolutions proposed by the Management and Supervisory Boards with a large majority.
Dr. Simon Nebel, Chair of the Supervisory Board, said: “We are very happy to hold this year’s AGM with personal attendance and we thank our shareholders for their participation, confidence, and long-standing support. We are glad that with Dr. Elisabeth Lackner and Ulrich Kinzel, we could attract two renowned experts with a long-standing track record in the life sciences and healthcare industry as well as extensive capital market expertise for the supervisory board. I am very much looking forward to the cooperation.”
Dr. Andreas Grassauer, Marinomed’s CEO, added: “Last year was a very successful one for Marinomed and with our augmented strategy 2025, we believe that we can accelerate our growth path. We will continue to build on our expertise in virology and immunology and expand into rare Rx indications where new treatment options are urgently needed.”
The full press release is available as download here: